CDSCO Approves Aurobindo CuraTeQ's Bevacizumab Biosimilar Bevqolva for Cancer Treatment
New Delhi: Aurobindo Pharma on Friday announced that its wholly owned subsidiary CuraTeQ Biologics Pvt Ltd has received marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for Bevqolva, a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum.
The company said the approval was granted under Form CT 23 and allows the manufacture of the biosimilar at CuraTeQ’s manufacturing facility located in Hyderabad.
According to the regulatory filing, Bevqolva will be marketed in two vial presentations -100 mg/4 mL and 400 mg/16 mL.
Bevacizumab is widely used in oncology treatment and is indicated for various types of cancers, including metastatic colorectal cancer. The biosimilar approval is expected to strengthen CuraTeQ Biologics’ oncology portfolio in India.
According to the company’s disclosure, the CDSCO approval marks another step in expanding CuraTeQ’s biosimilar business and manufacturing capabilities in the country.
